Recce Pharmaceuticals (ASX:RCE) secured clearance from an independent non-data safety review board to continue a phase 2 clinical trial evaluating the Recce 327 topical gel as a potential antibacterial product for acute skin infections, including diabetic foot infections, according to a Monday filing with the Australian bourse.
The disclosure follows a safety and efficacy review in which no serious adverse events were noted, the filing said.
Company shares fell almost 5% at market close on Monday.
Price (AUD): $0.48, Change: $-0.025, Percent Change: -4.95%
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。